Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome

Annals of Allergy, Asthma and Immunology

Volumn 82, Issue 2, 1999, Pages 185-191

  Forsyth, Linda M ^a   Preuss, Harry G ^a   MacDowell, Ana L ^a   Chiazze Jr , Leonard ^a   Birkmayer, George D ^b   Bellanti, Joseph A ^a,c  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Birkmayer Pharmaceuticals   (Austria)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENADA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0033014828     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62595-1     Document Type: Article

References (32)

1. Straus SE. History of chronic fatigue syndrome. Rev Infect Dis 1991;13 (suppl 1):S2-7.
2. Lloyd AR, Hickie I, Boughton CR, et al. Prevalence of chronic fatigue syndrome in an Australian population. Med J Aust 1990;153:522-528.
3. Bates DW, Schmitt W, Buchwald D, et al. Prevalence of fatigue and chronic fatigue syndrome in primary care practice. Arch Intern Med 1993;153: 2759-2765.
4. Buchwald D, Umali P, Umali D, et al. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest Health Care System. Ann Intern Med 1995;123:81-88.
5. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994;121: 953-959.
6. Komaroff AL, Buchwald DS. Chronic fatigue syndrome: an update. Annu Rev Med 1998;49:1-13.
7. Sharpe MC, Archard LC, Banatvala JE, et al. A report-chronic fatigue syndrome: guidelines for research. J R Soc Med 1991;84:118-121.
8. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988;108:387-398.
9. Buchwald D, Komaroff AL. Review laboratory findings for patients chronic fatigue syndrome. Rev Infect Dis 1991;13(suppl):S12-18.
10. Lloyd AR, Wakefield D, Boughton CR, Dwyer JM. Immunological abnormalities in the chronic fatigue syndrome. Med J Aust 1989;151: 122-124.
11. Klimas NG, Fernando FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990;28:1403-1410.
12. Mawle AC, Nisenbaum R, Dobbins JG, et al. Immune responses associated with chronic fatigue syndrome: a case-controlled study. J Infect Dis 1997; 136-141.
13. Lloyd A, Hickie I, Wakefield D, et al. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Amer J Med 1990;89: 562-568.
14. Peterson PK, Shepard J, Macres M, et al. A controlled trial of intravenous G in chronic fatigue syndrome. Amer J Med 1990;89:554-560.
15. Lloyd A, Hickie I, Hickie C, et al. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. Clin Exp Immunol 1992;87:76-79.
16. Peakman M, Deale A, Field R, et al. Clinical improvements in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation. Clin Immunopathol 1997;82: 83-91.
17. Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995;274:961-967.
18. Sumaya CV. Serological and virologic epidemiology of Epstein-Barr virus: relevance to chronic fatigue syndrome. Rev Infect Dis 1991;13 (suppl): S19-25.
19. Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome, lack of efficacy in a placebo-controlled trial. N Eng J Med 1988;319:1692-1698.
20. See DM, Tilles JG. Alpha interferon treatment of patients with chronic fatigue syndrome. Immunol Invest 1996; 25:153-164.
21. Brook MG, Bannister BA, Weir WRC. Interferon-alpha therapy for patients with chronic fatigue syndrome [Letter]. J Infect Dis 1993; 168:791-792.
22. Bellanti JA, Forsyth LM, MacDowell AL, Preuss HG. Chronic fatigue syndrome (CFS): unraveling a new dilemma. J Am College Nutr 1998 (in press).
23. Sudadolnik RJ, Reichenbach NK, Hitzges P, et al. Upregulation of the 2-5 A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994;18 (suppl):S96-104.
24. Sudadolnik RJ, Peterson DL, O'Brien K, et al. Biochemical evidence for a novel low molecular weight 2-5 A-Dependent Rnase L in chronic fatigue syndrome. J Interferon Res 1997;17: 377-385.
25. Straus SE, Dale JK, Wright R, Metcalfe DD. Allergy and the chronic fatigue syndrome. J Allergy Immunol 1988;81:791-795.
26. Birkmayer JGD, Vrecko C, Vole D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH)-new therapeutic approach to Parkinson's disease, comparison of oral and parenteral application. Acta Neurol Scand 1993;87 Suppl 146:32-35.
27. Birkmayer JGD. Coenzyme nicotinamide adenine dinucleotide, new therapeutic approach for improving dementia of the Alzheimer type. Ann CHn Lab Sci 1996;26:1-9.
28. Birkmayer JD, Birkmayer W. The coenzyme nicotinamide adenine dinucleotide (NADH) as biological antidepressive agent experience with 205 patients. New Trend in Clin Neuropharm 1991;5:75-86.
29. Bellanti JA, Forsyth LM, MacDowell-Carneiro AL, Birkmayer GD, Preuss HG. NADH and chronic fatigue syndrome (CFS): a new therapeutic approach [Abstract]. Ann Allergy Asthma Immunol 1998; 80:82.
30. Bushehri N, Jarrell ST, Lieberman S, et al. Oral reduced b-nicotinamide adenine dinucleotide (NADH) and lipid profile in hypertensive rats (SHR). J Geriatric Nephr Urol 1998; (in press).
31. Bakheit AMO, Behan PO, Dinan TG, et al. Possible upregulation of hypothalamic 5-hydrotryptamine receptors in patients with postviral fatigue syndrome. Br Med J 1992;304:1010-1012.
32. Forsyth LM, MacDowell-Carneiro AL, Birkmayer GD, et al. The measurement of 5-HIAA urinary concentrations as a predictive marker of efficacy of NADH in chronic fatigue syndrome (manuscript in preparation) 1998.